Alkali metal and alkaline-earth metal salts of acetaminophen

• US 6,160,020 A
• Filed: 06/19/1998
• Issued: 12/12/2000
• Est. Priority Date: 12/20/1996
• Status: Expired due to Term

• Current Assignee: McNeil-PPC Incorporated (Johnson & Johnson)
• Original Assignee: McNeil-PPC Incorporated (Johnson & Johnson)
• Inventors: Rey, Max, Higgins, John D. III, Nadig, David, Ohannesian, Lena A., Martellucci, Stephen A.
• Primary Examiner(s): Cook, Rebecca
• Application Number:
  US09/100,284
• Time in Patent Office: 907 Days
• Field of Search: 564/215, 514/629
• US Class Current: 514/629
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07C 233/25 having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Abstract

Isolated salts of acetaminophen are disclosed. Alkali metal and alkaline-earth metal salts of acetaminophen were formed by reacting the free acid of acetaminophen with the corresponding metal hydroxide and then immediately isolating the resulting salt. These salts have been found to be more water soluble and less bitter in taste than the free acid form of acetaminophen. The isolated salts may also be combined with other active ingredients.

Claims

1. An isolated alkali metal or alkaline-earth metal salt of acetaminophen.

2. The salt of claim 1 wherein the alkali metal is selected from the group consisting of lithium, sodium, potassium and cesium.

3. The salt of claim 1 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

4. The salt of claim 1 in a hydrated form.

5. The salt of claim 1 in an anhydrous form.

6. The salt of claim 5 wherein the alkaline-earth metal is calcium.

7. A solid orally adminsterable dosage form comprising a therapeutically effective amount of the salt of claim 1.

8. A method of treating a mammal in need of an analgesic or antipyretic agent, comprising the oral administration of a therapeutically effective amount of an isolated alkali metal or alkaline-earth metal salt of acetaminophen.

9. The method of claim 8 wherein the alkali metal is selected from the group consisting of lithium, sodium, cesium and potassium.

10. The method of claim 8 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

11. The method of claim 8 wherein the salt is in a hydrated form.

12. The method of claim 8 wherein the salt is in an anhydrous form.

13. The method of claim 12 where in the alkaline-earth metal is calcium.

14. A method of eliciting an analgesic or antipyretic response in a mammal, comprising the oral administration of a therapeutically effective amount of an isolated alkali metal or alkaline-earth metal salt of acetaminophen.

15. The method of claim 14 wherein the alkali metal is selected from the group consisting of lithium, sodium, cesium and potassium.

16. The method of claim 14 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

17. The method of claim 14 wherein the salt is in a hydrated form.

18. The method of claim 14 wherein the salt is in an anhydrous form.

19. The method of claim 18 wherein the alkaline-earth metal is calcium.

20. The isolated compound:

##STR3## wherein n is 1 or 2, M is alkali metal when n is 1 and M is alkaline-earth metal when n is 2 and x is from 0 to about 10.

21. The compound of claim 20 wherein the alkali metal is selected from the group consisting of sodium potassium, cesium and lithium.

22. The compound of claim 20 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

23. The compound of claim 20 in a hydrated form.

24. The compound of claim 20 in an anhydrous form.

25. The compound of claim 24 wherein the alkaline-earth metal is calcium.

26. A method of preparing an isolated alkali metal or alkaline-earth metal salt of acetaminophen, comprising:

reacting acetaminophen with an alkali metal or alkaline-earth metal metal hydroxide in the presence of a solvent to form a reaction mixture and

immediately recovering the resulting salt from the reaction mixture.

27. The method of claim 26 wherein the solvent is water or a water-miscible organic liquid.

28. The method of claim 26 wherein the salt is recovered by crystallization with a water-miscible solvent.

29. The method of claim 26 wherein the salt is recovered by lyophilization.

30. A method of preparing an anhydrous, isolated salt of acetaminophen, comprising:

contacting a monovalent metal salt of acetaminophen with a divalent metal cation whereby a divalent metal salt of acetaminophen is formed via a cation exchange reaction and

immediately recovering the resulting anhydrous, divalent metal salt of acetaminophen.

31. The method of claim 30 wherein an aqueous solution or slurry of said monovalent metal salt of acetaminophen is contacted with said divalent metal cation and the resulting anhydrous salt is recovered by vacuum drying.

32. The method of claim 30 wherein the anhydrous salt is C₁₆ H₁₆ N₂ O₄ Ca.

33. The method of claim 32 wherein said anhydrous salt is formed by a cation exchange reaction between acetaminophen sodium and calcium chloride.

34. A composition comprising an isolated alkali metal or alkaline-earth metal salt of acetaminophen and at least one other active ingredient selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators and, sleep-inducing agents or a mixture thereof.

35. The composition of claim 34 wherein the alkali metal is selected from the group consisting of lithium, sodium, potassium and cesium.

36. The composition of claim 34 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

37. The composition of claim 34 wherein the salt is in a hydrated form.

38. The composition of claim 34 wherein the salt is in an anhydrous form.

39. The composition of claim 38 wherein the alkaline-earth metal is calcium.

40. The composition of claim 37 comprising a solid orally administerable dosage form.

41. A method of treating a mammal in need of an analgesic or antipyretic agent, comprising the oral administration of a therapeutically effective amount of the composition of claim 34.

42. The method of claim 41 wherein the alkali metal is selected from the group consisting of lithium, sodium, cesium and potassium.

43. The method of claim 42 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

44. The method of claim 41 wherein the salt is in a hydrated form.

45. The method of claim 41 wherein the salt is in an anhydrous form.

46. A method of eliciting an analgesic or antipyretic response in a mammal, comprising the oral administration of a therapeutically effective amount of the composition of claim 34.

47. The method of claim 46 wherein the alkali metal is selected from the group consisting of lithium, sodium, cesium and potassium.

48. The method of claim 46 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

49. The method of claim 46 wherein the salt is in a hydrated form.

50. The method of claim 46 wherein the salt is in an anhydrous form.

51. A pharmaceutical composition comprising the isolated compound ##STR4## wherein n is 1 or 2, M is alkali metal when n is 1 and M is alkaline-earth metal when n is 2 and x is from 0 to about 10, and at least one other active ingredient selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics and bronchodilators or a mixture thereof.

52. The composition of claim 51 wherein the alkali metal is selected from the group consisting of sodium, potassium, cesium and lithium.

53. The composition of claim 51 wherein the alkaline-earth metal is selected from the group consisting of calcium and magnesium.

54. The composition of claim 51 wherein the isolated compound is in a hydrated form.

55. The composition of claim 51 wherein the isolated compound is in an anhydrous form.

56. The composition of claim 51 wherein the analgesic is selected from the group consisting of acetyl salicylic acid, indomethacin, an optically active isomer or racemate of ibuprofen, naproxen, flurbiprofen, carprofen, tiaprofenic acid, cicloprofen, ketoprofen, ketorolac, etodolac, indomethacin, sulindac, fenoprofen, diclofenac, piroxicam, benzydomine, nabumetone, tramadol, codeine, oxycodone, hydrocodone, flosulide, nimesulide, celecoxib, 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole, meloxicam, nabumetone and etodolac;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

57. The composition of claim 51 wherein the decongestant is selected from the group consisting of pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

58. The composition of claim 51 wherein the expectorant is selected from the group consisting of guaifenesin, glyceryl guaiacolate, terpin hydrate, ammonium chloride, N acetylcysteine and bromhexine, ambroxol, domiodol and 3-iodo-1,2-propanediol;

or a pharmaceutically acceptable salt thereof and or a mixture thereof.

59. The composition of claim 51 wherein the antitussive is selected from the group consisting of dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben and benzonatate;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

60. The composition of claim 51 wherein the antihistamine is selected from the group consisting of chlorpheniramine, brompheniramine, dexchlorpheniramne, dexbrompheniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, hydroxtzine, pyrilamine, azatadine, promethazine, acrivastine, astemizole, cetirizine, ketotifen, loratidine, temelastine, terfenadine, norastemizole and fexofenadine;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

61. The composition of claim 51 wherein the gastrointestinal agent is selected from the group consisting of atropine, clidinium and dicyclomine, aluminum hydroxide, bismuth subsalicylate, bismuth subcitrate, simethicone, calcium carbonate, magaldrate, cimetidine, famotidine, nizatidine, ranitidine, phenolphthalein, casanthrol, sucralfate and sucralfate humid gel, metoclopramide, eisaprode, omeprazole, diphenoxylate and loperamide;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

62. The composition of claim 51 wherein the other active ingredient is a diuretic which is selected from the group consisting of caffeine and pamabrom.

63. The composition of claim 51 wherein the other active ingredient is a bronchodilator which is selected from the group consisting of terbutaline, aminophylline, pinephrine, isoprenaline, metaproterenol, bitoterol, theophylline and albuterol;

or a pharmaceutically acceptable salt thereof or a mixture thereof.

64. The composition of claim 51 wherein the other active ingredient is a sleep-inducing agent which sleep-inducing agent is selected from the group consisting of melatonin, estazolam, zolpidem and promethacine;

or a pharmaceutically acceptable salt thereof or a mixture thereof.